Stock futures are little changed ahead of big tech earnings and Fed meeting decision: Live updates
Stock futures were lower Sunday night ahead of a busy earnings week and Fed policy decision.
Stock futures are little changed ahead of big tech earnings and Fed meeting decision: Live updates
Stock futures were lower Sunday night ahead of a busy earnings week and Fed policy decision.
Stock futures are little changed ahead of big tech earnings and Fed meeting decision: Live updates
Stock futures were lower Sunday night ahead of a busy earnings week and Fed policy decision.
Stock futures fall ahead of big tech earnings and Fed meeting decision: Live updates
Stock futures were lower Sunday night ahead of a busy earnings week and Fed policy decision.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry’s top players in the hot seat over the next few years.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry’s top players in the hot seat over the next few years.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry’s top players in the hot seat over the next few years.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry’s top players in the hot seat over the next few years.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry’s top players in the hot seat over the next few years.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry’s top players in the hot seat over the next few years.